Kenya National Cancer Control Programme (NCCP) FHIR Implementation Guide, published by Digital Health Agency (DHA), Kenya. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/IntelliSOFT-Consulting/nccpFHIRIG/ and changes regularly. See the Directory of published versions
CodeSystem: Kenya OCM Protocol Markers Code System
Biomarker and molecular marker codes used for treatment protocol selection.
This Code system is referenced in the definition of the following value sets:
This case-sensitive code system https://nshr-uat.sha.go.ke/fhir/CodeSystem/ocm-protocol-markers-cs defines the following codes:
| Code | Display | Definition |
| HER2-POSITIVE |
HER2 Positive |
HER2/neu overexpression or amplification detected. |
| HER2-NEGATIVE |
HER2 Negative |
No HER2/neu overexpression or amplification. |
| ER-POSITIVE |
ER Positive |
Oestrogen receptor positive. |
| ER-NEGATIVE |
ER Negative |
Oestrogen receptor negative. |
| PR-POSITIVE |
PR Positive |
Progesterone receptor positive. |
| PR-NEGATIVE |
PR Negative |
Progesterone receptor negative. |
| TRIPLE-NEGATIVE |
Triple Negative |
ER-, PR-, HER2- breast cancer. |
| KRAS-MUTANT |
KRAS Mutant |
KRAS mutation detected. |
| KRAS-WILD-TYPE |
KRAS Wild-type |
No KRAS mutation. |
| BRAF-V600E |
BRAF V600E Mutant |
BRAF V600E mutation detected. |
| PD-L1-POSITIVE |
PD-L1 Positive |
PD-L1 expression ≥1%. |
| PD-L1-NEGATIVE |
PD-L1 Negative |
PD-L1 expression <1%. |
| MSI-HIGH |
MSI-High |
Microsatellite instability high. |
| MSI-LOW |
MSI-Low / MSS |
Microsatellite instability low or stable. |
| EGFR-MUTANT |
EGFR Mutant |
EGFR mutation detected. |
| ALK-POSITIVE |
ALK Positive |
ALK rearrangement detected. |
| NOT-TESTED |
Not Tested |
Biomarker testing not performed. |
Description of the above table(s).